Omeros | OMER - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Adma Biologics USD 76.41M 6.8M 2025-12
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cytokinetics USD 200.58M 4.46M 2026-03
Gilead Sciences USD 23.52B 18.55B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Immunic USD 23.33M 2.67M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Knight Therapeutics CAD 126.9M 8.29M 2025-12
MacroGenics USD 21.2M 32.13M 2026-03
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 172.75M 20.93M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Rockwell Medical USD 30.41M 1.11M 2025-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03
Xoma USD 22.84M 1.67M 2024-09